Table 3.
Characteristics of People Living With Human Immunodeficiency Virus Initiating Antiretroviral Therapy (ART) of ≥45 Days’ Duration and With an Available Weight Measure at 12 Months (±6 Months) After ART Initiation Date, 2007–2016, in Participating North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) Cohorts (Those With ≥50 Individuals Receiving Each Core Class), Stratified by Class of Regimen Core
| Characteristic | Total No. | NNRTI-Based (n = 8200) |
PI-Based (n = 5215) |
INSTI-Based (n = 3652) |
Combined (N = 17 067) |
Interclass P Value |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sex assigned at birth | 17 067 | <.001a | ||||||||
| Male | 0.91 | (7455) | 0.81 | (4229) | 0.85 | (3120) | 0.87 | (14 804) | ||
| Female | 0.09 | (745) | 0.19 | (986) | 0.15 | (532) | 0.13 | (2263) | ||
| Race/ethnicity | 16 320 | .28a | ||||||||
| White, non-Hispanic | 0.39 | (3070) | 0.38 | (1888) | 0.39 | (1380) | 0.39 | (6338) | ||
| Non-white | 0.61 | (4721) | 0.62 | (3081) | 0.61 | (2180) | 0.61 | (9982) | ||
| HIV transmission risk | 17 067 | <.001a | ||||||||
| MSM | 0.39 | (3220) | 0.31 | (1598) | 0.51 | (1852) | 0.39 | (6670) | ||
| IDU, including MSM/IDU | 0.12 | (958) | 0.14 | (748) | 0.08 | (280) | 0.12 | (1986) | ||
| Heterosexual | 0.14 | (1130) | 0.19 | (997) | 0.19 | (678) | 0.16 | (2805) | ||
| Other/unknown | 0.35 | (2892) | 0.36 | (1872) | 0.23 | (842) | 0.33 | (5606) | ||
| Age, y | 17 067 | 42 (32, 51) | 41 (31, 50) | 38 (28, 48) | 41 (31, 50) | <.001c | ||||
| Baseline weightb, kg | 15 021 | 78 (69, 89) | 76 (67, 87) | 77 (67, 89) | 77 (68, 89) | <.001c | ||||
| Weight at 1 y after ARTb, kg | 17 067 | 80 (70, 91) | 79 (69, 91) | 80 (70, 93) | 80 (70, 91) | .061c | ||||
| Baseline BMIb, kg/m2 | 14 452 | 25 (22, 28) | 25 (22, 28) | 25 (22, 29) | 25 (22, 28) | <.001c | ||||
| Baseline CD4+ countb, cells/µL | 15 227 | 315 (186, 450) | 266 (112, 406) | 368 (194, 535) | 310 (164, 458) | <.001c | ||||
| Baseline log10 HIV-1 RNAb | 14 525 | 4.6 (4.0, 5.0) | 4.7 (4.1, 5.2) | 4.6 (4.1, 5.1) | 4.6 (4.1, 5.1) | <.001c | ||||
| Year of ART initiationb | 17 067 | 2010 (2008, 2012) | 2010 (2009, 2011) | 2014 (2012, 2015) | 2011 (2009, 2013) | <.001c | ||||
| Incident diabetes mellitus | 17 067 | <.001a | ||||||||
| No | 0.98 | (7999) | 0.98 | (5116) | 0.99 | (3605) | 0.98 | (16 720) | ||
| Yes | 0.02 | (201) | 0.02 | (99) | 0.01 | (47) | 0.02 | (347) | ||
| Follow-up timeb, y | 17 067 | 2.32 (0.72, 4.47) | 1.75 (0.35, 3.32) | 1.12 (0.31, 2.29) | 1.83 (0.48, 3.64) | <.001c |
Numbers in parentheses after proportions are frequencies. N is the number of nonmissing values.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; HIV-1, human immunodeficiency virus type 1; IDU, injection drug use; INSTI, integrase strand transfer inhibitor; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
aPearson χ 2 test.
bMedian (lower quartile, upper quartile).
cKruskal-Wallis test.